Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

t on the pharmacokinetics of sitagliptin based on a composite analysis of available pharmacokinetic data, including subjects of white, Hispanic, black, Asian, and other racial groups. Drug Interactions In Vitro Assessment of Drug Interactions Sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4. Sitagliptin is a p-glycoprotein substrate, but does not inhibit p-glycoprotein mediated transport of digoxin. Based on these results, sitagliptin is considered unlikely to cause interactions with other drugs that utilize these pathways. Sitagliptin is not extensively bound to plasma proteins. Therefore, the propensity of sitagliptin to be involved in clinically meaningful drug-drug interactions mediated by plasma protein binding displacement is very low. In Vivo Assessment of Drug Interactions Effects of Sitagliptin on Other Drugs In clinical studies, as described below, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, warfarin, or oral contraceptives, providing in vivo evidence of a low propensity for causing drug interactions with substrates of CYP3A4, CYP2C8, CYP2C9, and organic cationic transporter (OCT). Digoxin: Sitagliptin had a minimal effect on the pharmacokinetics of digoxin. Following administration of 0.25 mg digoxin concomitantly with 100 mg of JANUVIA daily for 10 days, the plasma AUC of digoxin was increased by 11%, and the plasma Cmax by 18%. Metformin: Co-administration of multiple twice-daily doses of sitagliptin with metformin, an OCT substrate, did not meaningfully alter the pharmacokinetics of metformin in patients with type 2 diabetes. Therefore, sitagliptin is not an inhibitor of OCT-mediated transport. Sulfonylureas: Single-dose pharmacokinetics of glyburide, a CYP2C9 substrate, was not meaningfully altered in subjects receiving multiple
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:7/30/2014)... , July 30, 2014 Reportlinker.com ... available in its catalogue: mHealth and ... http://www.reportlinker.com/p0356852/mHealth-and-Home-Monitoring-–-6th-Edition.html Executive summary ... delivered, leading to better outcomes, decreased costs and ... for mHealth solutions is still in an early ...
(Date:7/30/2014)... and KISSING, Germany , ... distributor of a single use and computer-assisted ("robotic") colonoscopy ... Shamir , a worldwide recognized medical device executive, as ... Mr. Shamir is a highly respected global visionary ... assignment he served as President and Chief Executive Officer ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014  Eisai ... announced today that an article based on post-hoc analyses from ... Weight Loss While on Lorcaserin, Diet, and Exercise as a ... the online issue of Obesity , the official peer ... analyses was to identify whether there is an early treatment ...
Breaking Medicine Technology:mHealth and Home Monitoring - 6th Edition 2mHealth and Home Monitoring - 6th Edition 3mHealth and Home Monitoring - 6th Edition 4mHealth and Home Monitoring - 6th Edition 5mHealth and Home Monitoring - 6th Edition 6mHealth and Home Monitoring - 6th Edition 7mHealth and Home Monitoring - 6th Edition 8mHealth and Home Monitoring - 6th Edition 9mHealth and Home Monitoring - 6th Edition 10mHealth and Home Monitoring - 6th Edition 11invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... Calif., Jan. 16 Cerimon,Pharmaceuticals, Inc., announced today ... clinical studies of its once-,daily topical diclofenac sodium ... the studies, designated the "SUPPORT" (Stop Underlying Pain ... will assess the,efficacy and safety of Cerimon,s patch ...
... Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today announced that ... with the first patient being treated on January ... evaluate the safety, tolerability and,pharmacokinetic profile of SGX523, ... cMET receptor tyrosine,kinase., The Phase I clinical ...
Cached Medicine Technology:Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain 2Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain 3SGX Initiates Phase I Trials for SGX523 2SGX Initiates Phase I Trials for SGX523 3
(Date:7/30/2014)... -- Some obese people have a genetic mutation that ... brains when they see food, researchers report. Gaining ... of pleasure and gratification at the sight of high-calorie ... prevent overeating, the scientists suggested. More than one-third ... caused by a combination of overeating, a lack of ...
(Date:7/30/2014)... July 30, 2014. A new network of 25 regional ... Trials Network (NIH StrokeNet) is working to change ... Despite advances of the last two decades, stroke ... causes death or disability for 795,000 Americans. The numbers ... the population. , To accelerate the pace of ...
(Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased to ... will serve as chair. The board was voted upon ... Conference in Houston, Texas July 10-12. , “The ... us. From the rollout of the first EDNF Center ... Medical Center to our September physicians conference to a ...
(Date:7/30/2014)... July 30, 2014 As the controversy ... in gynecological surgeries continues to grow, Bernstein Liebhard LLP ... those calling for a ban on uterine morcellation. According ... was diagnosed with leiomyosarcoma following a hysterectomy that involved ... of her diagnosis, the aggressive cancer had progressed to ...
(Date:7/30/2014)... 30, 2014 Hospitals continually face ... of care that their practitioners provide. During a ... Rowe, discussed the importance of establishing effective peer ... performance and quality of care. , With ... Mr. Rowe elaborated on setting performance expectations, conducting ...
Breaking Medicine News(10 mins):Health News:Gene Mutation May Make Food More Tempting 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3
... , BUFFALO, N.Y., July 15 CTG (Nasdaq: ... company, announced today that it was named by Healthcare Informatics ... providers, the Healthcare Informatics 100 (HCI 100). CTG was named to ... healthcare provider market. In addition to other large healthcare IT consulting ...
... , , DALLAS, ... Enterprises, LLC announced today that the company has been awarded ... Medicaid Services (CMS) to serve as the Medicare Administrative Contractor ... The full period of contract performance is five years, including ...
... WOODCLIFF LAKE, N.J., July 15 Par Pharmaceutical Companies, Inc. (NYSE: ... live webcast on Tuesday, August 4, 2009 at 9:00 am EDT to review ... its financial results on August 4 before the market opens. The earnings release ... , , Access to the live webcast can ...
... , , NAPLES, Fla., July 15 ... parents, has gathered the top ten issues that affect caregivers. These issues ... ( www.agingcare.com/Community ), where caregivers connect and communicate with one ... paid for caregiving. Oftentimes, adult children have to give up their ...
... July 15 The overall OTC market grew 3.2% during non-recession ... Impact of Recessions on the U.S. OTC Market ... , The impact of recessions on ... by private-label products and is reflected in slower growth rates. The ...
... the way for future targeted treatment, , WEDNESDAY, July ... cells appear to be important predictors of the spread ... measured levels of circulating endothelial cells and endothelial progenitor ... with metastatic cancer and 20 healthy children. Circulating endothelial ...
Cached Medicine News:Health News:CTG Named to Healthcare Informatics Annual Ranking of the Top 100 Healthcare IT Providers 2Health News:CTG Named to Healthcare Informatics Annual Ranking of the Top 100 Healthcare IT Providers 3Health News:CMS Selects TrailBlazer Health Enterprises to Administer Medicare Program in Arkansas, Louisiana and Mississippi 2Health News:Caring for Elderly Parents Is Tougher During Hard Times 2Health News:OTC Market Is Not Largely Impacted by Recession; However, Prominent Growth Remains Only in Some Categories, According to Kline 2Health News:Rare Cells Linked to Pediatric Cancers 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: